Karo Pharma AB (OSTO:KARO) ROCE % : 0.00% (As of Jun. 2022)

View and export this data going back to 1998. Start your Free Trial

What is Karo Pharma AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Karo Pharma AB's annualized ROCE % for the quarter that ended in Jun. 2022 was 0.00%.

Karo Pharma AB ROCE % Historical Data

The historical data trend for Karo Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB ROCE % Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

2.64

9.87

2.63

3.38

2.02

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
ROCE %	Get a 7-Day Free Trial															6.97	1.68	5.37	-2.61	-

Karo Pharma AB ROCE % Calculation

Karo Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	195.417	/	( ( (12517.499 - 5221.467)	+	(12593.418 - 586.339) )	/ 2 )
	=	195.417	/	( (7296.032	+	12007.079)	/ 2 )
	=	195.417	/	9651.5555
	=	2.02 %

Karo Pharma AB's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	0	/	( ( (12593.418 - 586.339)	+	(18492.8 - 626) )	/ 2 )
	=	0	/	( ( 12007.079	+	17866.8 )	/ 2 )
	=	0	/	14936.9395
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

Karo Pharma AB (OSTO:KARO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Karo Pharma AB ROCE % Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (OSTO:KARO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OSTO:KARO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.